Cardiology 127(1) 1–72 (2014)	127 1 14	print ISSN 0008–6312	online e-ISSN 1421–9751	www.karger.com/crd

CARDIOLOGY International Journal of

Cardiovascular Medicine, Surgery, Pathology and Pharmacology

Editorial

20 Dyspnea and Reversibility of Antiplatelet Agents: Ticagrelor, Elinogrel, Cangrelor, and Beyond Serebruany, V.L.; Sibbing, D.; DiNicolantonio, J.J. (Towson, Md.)

Editorial Comments

- 28 Pigment Epithelial-Derived Factor and Acute Coronary Syndrome: A Novel Protective Biomarker but Not for Routine Clinical Use at Present Thadani, U.; Latif, F. (Oklahoma City, Okla.)
- 51 Avoid Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy Link, M.S. (Boston, Mass.)
- 53 The Matter of Matrix: Recurrence of Atrial Fibrillation after a Surgical Maze Procedure

Knutson, C.; Akhrass, P.; Budzikowski, A.S. (Brooklyn, N.Y.)

Original Research

- 31 The Association Study of Plasma Levels of Pigment Epithelium-Derived Factor with Acute Coronary Syndrome in the Chinese Han Population Liu, J.; Wang, S.; Shi, J.; Guo, Y.; Liu, J.; Tao, T.; Zhu, P. (Beijing)
- 38 Exercise-Induced Muscle Vasodilatation and Treadmill Exercise Test Responses in Individuals without Overt Heart Disease

Nunes, R.A.B.; Giampaoli, V.; de Freitas, H.F.G.; da Costa Pereira, A.; Araújo, F.; Correia, G.F.; Rondon, M.U.P.B.; Negrão, C.E.; Mansur, A.J. (São Paulo)

45 Low Levels of Low-Density Lipoprotein Cholesterol: A Negative Predictor of Survival in Elderly Patients with Advanced Heart Failure

Charach, G.; Rabinovich, A.; Ori, A.; Weksler, D.; Sheps, D.; Charach, L.; Weintraub, M.; George, J. (Tel Aviv)

55 Prediabetes and Short-Term Outcomes in Nondiabetic Patients after Acute ST-Elevation Myocardial Infarction

Tian, L.; Zhu, J.; Liu, L.; Liang, Y.; Li, J.; Yang, Y. (Beijing)

62 The Analysis of microRNA Expression Profiling for Coronary Artery Disease

Li, K.; Zhang, T.; Fan, H.; Li, Q. (Shanghai); Ito, W.; Torzewski, J. (Immenstadt); Guo, J.; Liu, Z. (Shanghai)

(Continued on inside front cover)

S. Karger Medical and Scientific Publishers Basel · Freiburg · Paris · London · New York · New Delhi · Bangkok · Beijing · Tokyo · Kuala Lumpur · Singapore · Sydney



(Continued from front cover)

Turning Basic Research into Clinical Success

1 Posttraumatic Stress Disorder and Cardiometabolic Disease

Levine, A.B. (Pittsburgh, Pa.); Levine, L.M. (Bedford, Mass.); Levine, T.B. (Pittsburgh, Pa.)

Letters to the Editor

- **25 Uric Acid Level in Patients with Kidney Disease** Balta, S.; Demir, M.; Demirkol, S.; Kucuk, U.; Unlu, M.; Arslan, Z. (Ankara)
- 26 Uric Acid Level Should Be Stratified in Order to Better Evaluate Inflammatory Status Erayman, A. (Kahramanmaras)
- 70 Prooxidant-Antioxidant Balance and Risk Factors of Coronary Artery Disease Kawada, T. (Tokyo)

Letter to the Editor/Reply

71 Authors' Reply Rahsepar, A.A.; Khorashadizadeh, F.; Ghayour-Mobarhan, M. (Mashhad); Ferns, G. (Falmer)

KARGER

International Journal of Cardiovascular Medicine, Surgery, Pathology and Pharmacology

Founded 1937 as 'Cardiologia' by Bruno Kisch and Wilhelm Löffler, continued by R. Hegglin (1962–1969), I. Mahaim (1962–1965), P. Moret (1966–1969), P.M. Galletti (1966–1979), Jan J. Kellermann (1980–1990) and Joseph S. Alpert (1990–2005)

Incorporating Heart Drug (published 2001–2005)

Editorial Board

E. Abadie, Saint Denis D.H. Adams, New York, N.Y. C.W. Akins, Boston, Mass. I.S. Alpert, Tucson, Ariz. E.A. Amsterdam, Davis, Calif. W.S. Aronow, Valhalla, N.Y. I.I. Badimon, New York, N.Y. A. Battler, Petah Tikva I. Bax, Leiden R.C. Becker, Durham, N.C. G.A. Beller, Charlottesville, Va. P.C. Block, Atlanta, Ga. R.O. Bonow, Chicago, Ill. A.S. Budzikowski, Brooklyn, N.Y. A.J. Camm, London B.A. Carabello, Houston, Tex. K. Chatterjee, Iowa City, I.A. P.F. Cohn, Stony Brook, N.Y. J. Coromilas, New Brunswick, N.J. M.H. Crawford, San Francisco, Calif. I.E. Dalen, Tucson, Ariz. S. Dalla Volta, Padova P.C. Deedwania, Fresno, Calif.

A.N. De Maria, San Diego, Calif. J.A. Elefteriades, New Haven, Conn. U. Elkayam, Los Angeles, Calif. C. Erol, Ankara M.D. Ezekowitz, Wynnewood, Pa. R. Ferrari, Ferrara G. Filippatos, Athens G.I. Fishman, New York, N.Y. K. Fox, London G.S. Francis, Minneapolis, Minn. V. Fuster, New York, N.Y. B.J. Gersh, Rochester, Minn. W. Gersony, New York, N.Y. J.P. Gold, Toledo, Ohio R.J. Goldberg, Worcester, Mass. M.E. Goldman, New York, N.Y. P.J. Goldschmidt, Miami, Fla. J. Gore, Worcester, Mass. J.L. Halperin, New York, N.Y. Z.-X. He, Beijing D. Heistad, Iowa City, Iowa E.M. Herrold, Brooklyn, N.Y. G. Heusch, Essen

(Continued on next page)

Associate Editors

Editor-in-Chief

D. Atar, Oslo H. Boudoulas, Athens J.A. Franciosa, New York, N.Y. I.J. Gelb, Boca Raton, Fla. X. Huang, Boca Raton, Fla. J.T. Kassotis, Brooklyn, N.Y. W. Ko, New York, N.Y. B.S. Lewis, Haifa A.B. Miller, Jacksonville, Fla. D.J. Sahn, Portland, Oreg. S. Sasayama, Kyoto J. Somberg, Chicago, Ill. H. Taegtmeyer, Houston, Tex.

Jeffrey S. Borer, New York, N.Y.

KARGER

(Continued)

Editorial Board

L.D. Hillis, San Antonio, Tex. C.A. Hochreiter, New York, N.Y. M. Hori, Osaka S.K.S. Huang, Temple, Tex. B.K. Kantharia, Houston, Tex. J.S. Karliner, San Francisco, Calif. R.E. Kerber, Iowa City, Iowa N.Z. Kerin, Detroit, Mich. A. Kimchi, Los Angeles, Calif. R.N. Kitsis, Bronx, N.Y. P. Kligfield, New York, N.Y. X. Kong, Nanjing M.A. Konstam, Boston, Mass. J.B. Kostis, New Brunswick, N.J. P. Kowey, Wynnewood, Pa. K.H. Krieger, New York, N.Y. H. Krum, Melbourne, Vic. E. Kuschnir, Córdoba H. Kusuoka, Osaka W. Laskey, Albuquerque, N. Mex. J.M. Lazar, Brooklyn, N.Y. C.V. Leier, Columbus, Ohio M.C. Limacher, Gainesville, Fla. R.J. Lipicky, North Potomac, Md. T.F. Lüscher, Zurich F.I. Marcus, Tuscon, Ariz. A.J. Marian, Houston, Tex. J.D. Marmur, Brooklyn, N.Y. F.A. Martinez, Córdoba M.G. Massad, Chicago, Ill. P. Meier, London F.H. Messerli, New York, N.Y. J. Midwall, Atlantis, Fla. R.M. Mills, Raritan, N.J. J.E. Mitchell, Brooklyn, N.Y. R.J. Myerburg, Miami, Fla. J. Narula, Orange, Calif.

J.V. Nixon, Richmond, Va. I.S. Ockene, Worcester, Mass. H. Oh, Okavama J.A. Paraskos, Worcester, Mass. P. Pibarot, Quebec City, Que. B. Pitt, Ann Arbor, Mich. G.M. Pohost, Los Angeles, Calif. E.N. Prystowsky, Indianapolis, Ind. N. Reichek, Roslyn, N.Y. W.J. Remme, Rhoon R. Roberts, Ottawa W.C. Roberts, Dallas, Tex. R. Rosenhek, Vienna F. Ruschitzka, Zurich J.N. Ruskin, Boston, Mass. M.E. Sarano, Rochester, Minn. V.L. Serebruany, Towson, Md. D. Spodick, Worcester, Mass. M.R. Starling, Mesa, Ariz. P. Supino, Brooklyn, N.Y. J.L. Swain, La Jolla, Calif. K. Swedberg, Göteborg A.J. Tajik, Rochester, Minn. L. Tavazzi, Cotignola J.R. Teerlink, San Francisco, Calif. M. Tendera, Katowice U. Thadani, Oklahoma City, Okla. K. Thygesen, Aarhus N.K. Wenger, Atlanta, Ga. W.B. White, Farmington, Conn. J.T. Willerson, Houston, Tex. R.G. Williams, Los Angeles, Calif. K.K.-Y. Wu, Zhunan Town F. Zannad, Nancy B.L. Zaret, New Haven, Conn. D.P. Zipes, Indianapolis, Ind.

KARGER

Submission

Cardiology publishes original reports in research and observations pertaining to cardiovascular physiology, epidemiology, pharmacology, disease and therapy. Only original papers written in English are considered. The articles should be readily comprehensible to a reader who is fluent in English. Therefore, all manuscripts originating from non-English-speaking authors must be edited prior to submission to assure that standard English grammar and usage are observed. This may require help from a colleague or other editorial assistant. It must be evident from the covering letter that this has been done. Submissions that are not edited in this way will not be considered for publication until such editing has been achieved. Manuscripts should be submitted using the online submission website:

www.karger.com/crd

If you have any problems with submission, please contact:

S. Karger AG Editorial Office 'Cardiology' P.O. Box CH-4009 Basel (Switzerland) Tel. +41 61 306 1356 Fax +41 61 306 1434 E-Mail crd@karger.com

All manuscripts must be accompanied by a covering letter signed by all authors. Assurance should be given that the manuscript is not under simultaneous consideration by any other publication and that there are no conflicts of interest, see below. The preferred word processing package is Word for Windows[®]. Presentation of manuscripts should conform with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see N Engl J Med 1997;336:309–315).

Main Sections

1. Original Research

- Original Research Clinical Trial Design Submissions will be accepted reporting the study design protocols of planned clinical trials that have been appropriately registered with regulatory authorities. These submissions will be limited to 4500 words and 35 references.
- 3. Review
- 4. Turning Basic Research into Clinical Success One or two focused review articles are published in each issue, and should offer an overview of existing concepts and literature in a format assimilable to the largely clinical cardiologist readership, i.e. a readership base with limited sophistication as to methods and terminology associated with cell and molecular biology. Most manuscripts are submitted upon invitation. Authors planning to submit an unsolicited paper are requested to contact the Editorial Office with an outline of the intended contribution. All submissions are subject to peer review. These articles are available also to nonsubscribers in free access on the journal's website. Submissions should comprise no more than 4,500 words and 50 references. They should have an abstract of approximately 200 words and about 5 key words should be provided.
- 5. Letter to the Editor
- Letters to the Editor (max. 1,500 words, including references) are encouraged if they directly concern articles previously published in this journal and issues raised by those articles. The Editor reserves the right to submit copies of such letters to the authors of the articles concerned prior to publication in or-

der to permit them to respond in the same issue of the journal.

6. Novel Insights from Clinical Experience (formerly Case Reports)

Contributions to this section are expected to provide novel insight into a clinical problem. Submissions can be based on a single case or a number of similar cases. While a case report can describe an entirely novel clinical condition, it is unlikely that most case reports will provide such information. In the more common setting of a description of a wellrecognized condition, the most important aspect of the presentation, on which editorial judgments will be based, is the description of the new perspective(s) on the phenotype, pathophysiology, clinical presentation, evaluation strategy and/or management that can be drawn from the case findings.

We require that a highlighted box containing one or two bullet points on **Established facts** and **Novel insights** should be placed on the first page of the report. These should be selected to reinforce the novelty of the clinical observation.

The manuscript should be presented with an abstract (up to 200 words), brief introduction, case or case series description and results, followed by a discussion. Novel Insights from Clinical Experience should be no more than 2,500 words (including statements in the highlighted box) and should contain no more than 20 references.

Please note that case reports that are not submitted in this format will not be considered, and that such reports cannot be submitted as Letters to the Editor. 7. *Short Communications*

These manuscripts should not contain more than 2,000 words, including key words, essential references (not more than 15) and not more than 3 tables or figures. Such communications should represent complete, original studies and should be arranged in the same way as full length manuscripts.

8. Commentary

Authors who wish to contribute a manuscript to this category should contact the Editor. Commentaries should offer a more personalized perspective on a topic that will be of interest to the general readership, paralleling Editorials (defined as commentaries **invited** by the Editors or opinion pieces produced by members of our editorial board). All contributions to this category will be subject to editorial review for relevance for the readership, perception of topicality and general importance/interest, and quality of the submitted work. To submit a Letter to the Editor, see point 5. above.

Conditions

All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of *Cardiology* and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflict of Interest in Cardiovascular Publications

Declaration of potential conflict of interest should be part of each publication or presentation and be designated as one or more of four categories: (1) No relationship. (2) Relationship with a For Profit Organization. (3) Research relationship with a For Profit or Not For Profit Organization, which should be named. (4) Employee of a For Profit or Not For Profit Organization. For legal reasons, all authors are required during submission of their manuscript to complete and sign a **Copyright Transfer & Conflicts of Interest Statement**. The corresponding author must ensure that all authors have been asked to sign this form and to disclose any conflicts of interest.

Ethics

Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute's committee on human research. Further, they should also state that animal experiments conform to institutional standards.

Plagiarism

Authors should not appropriate the ideas, language or other elements of the work of others without providing appropriate attribution (i.e. 'plagiarism'). Plagiarism includes, but is not limited to, verbatim copying without quotation marks, close paraphrasing or summarization of sentences or narrative passages without citing source, and duplication of figures, graphs, images or data without acknowledgement of their origins. Authors also should not submit a previously published manuscript or a section of a previously published manuscript, even when re-titled, otherwise re-worded or augmented, without clearly identifying its relation to the author's earlier work (duplicate publication or 'self-plagiarism'). For additional guid-ance, see Roig, M.: Plagiarism and self-plagiarism: What every author should know. Biochemia Medica 2010:20:295-300.

Arrangement

Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

For submissions to Main Sections 1, 2 and 3:

Original Research, Original Research – Clinical Trial Design, and Review Papers

Abstract: The abstract is an essential and most read part of the paper. It should be printed on a separate page, up to 200 words, factual, free of abbreviations (except as specifically defined within the abstract text at first use) and should be structured as follows:

Objectives: Should describe the purpose of the study and the problem addressed; should include at least one sentence providing the rationale or justification for the study.

Methods: Should explain how the study was performed (samples and/or population, procedures, analytical methods).

Results: Should describe the main findings with specific data and their statistical significance, if possible. *Conclusions:* Should contain a succinct interpretation of the inferences to be drawn from results.

KARGER

© 2014 S. Karger AG, Basel

E-Mail karger@karger.com www.karger.com The Guidelines for Authors are available at: www.karger.com/crd_Guidelines

Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figures a legend, also prepared on a separate sheet. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 \times 223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author's name. b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions at http://www.karger.com/crd/).

Color illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.- per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org). Examples

(a) Papers published in periodicals: Sun J, Koto H, Chung KF: Interaction of ozone and allergen challenges on bronchial responsiveness and inflammation in sensitised guinea pigs. Int Arch Allergy Immunol 1997;112:191-195.

(b) Papers published only with DOI numbers:

Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

(c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996.

(d) Edited books: Parren PWHI, Burton DR: Antibodies against HIV-1 from phage display libraries: Mapping of an immune response and progress towards antiviral immunotherapy; in Capra JD (ed): Antibody Engineering. Chem Immunol. Basel, Karger, 1997, vol 65, pp 18-56.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists

Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material

Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and for-mats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author's Choice™

With this option the author can choose to make his article freely available online against a one-time fee of CHF 3,000.-. This fee is independent of any standard charges for supplementary pages, color images etc. which may apply. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research

The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peerreviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author's ChoiceTM service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH's Public Access Policy are available at http://publicaccess.nih. gov/FAQ.htm#a1

Self-Archiving

Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution's servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher's version, and must acknowledge the publisher's copyright. Authors selecting Karger's Au-thor's ChoiceTM feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Page Charges

There are no page charges for papers of 6 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.-. The allotted size of a paper is equal to approx. 18 manuscript pages (including tables, illustrations and references).

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer's errors, are charged to the author.

Reprints

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

KARGER

© 2014 S. Karger AG, Basel

E-Mail karger@karger.com www.karger.com

The Guidelines for Authors are available at:

www.karger.com/crd_Guidelines

General Information

Subscription Rates: Subscriptions run for

ISSN Print Edition: 0008-6312 ISSN Online Edition: 1421-9751

Journal Homepage: www.karger.com/crd

Publication Data: Cardiology is published 12 times a year. Volumes 127-129, each with 4 issues, appear in 2014

Copyright: © 2014 S. Karger AG, Basel (Switzerland). All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.

Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

a full calendar year. Prices are given per year. Personal subscription. Print or Online Print+Online combined CHF 608.-CHF 752 -EUR 498 -EUR 615 -USD 608 00 USD 752 00 postage and handling (added to print and print+online) CHF 88.80 Europe, CHF 129.60 Overseas EUR 72.00 USD 117.60 Institutional subscription: Print or Online Print+Online combined CHF 4053.-CHF 4458.-EUR 3321 -EUR 3654. USD 4053 00 USD 4458.00 postage and handling (added to print and print+online) CHF 111.- Europe, CHF 162.- Overseas EUR 90 -USD 147.00

Back Volumes and Single Issues: Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.com.

Bibliographic Indices: This journal is regularly listed in bibliographic services, including Current Contents® and PubMed/MEDLINE.

Photocopying: This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to

Copyright Clearance Center Inc.

222 Rosewood Drive

Danvers, MA 01923 (USA) A copy of the first page of the article must accompany payment. Consent does not extend to copying for general distribution, for promotion, for creating new

works, or for resale. In these cases, specific written permission must be obtained from the copyright owner, S. Karger AG, P.O. Box

CH-4009 Basel (Switzerland).

Subscription Orders: Orders can be placed at agencies, bookstores, directly with the Publisher

S. Karger AG Medical and Scientific Publishers Allschwilerstrasse 10 CH-4009 Basel Switzerland

+41 61 306 11 11 +41 61 306 12 34 e: karger@karger.com w: www.karger.com

(for courier services only: Allschwilerstrasse 10 CH-4055 Basel)

or further Karger offices or representatives:

Germany S. Karger GmbH

Postfach 79095 Freiburg Deutschland (Hausadresse: Wilhelmstrasse 20A, 79098 Freiburg) t: +49 761 45 20 70 f: +49 761 45 20 714 e: information@karger.de w: www.karger.de

1-2-23 Shiba Daimon Minato-ku Tokyo 105-0012 Japan t: +81 3 6435 6242 f: +81 3 6435 6244

USA S. Karger Publishers, Inc. 26 West Avon Road P.O. Box 529 Unionville, CT 06085 USA Toll free: +1 800 828 5479 t: +1 860 675 7834 f: +1 860 675 7302 e: karger@snet.net

France

Enter & Read Albertine Luginbuhl 23, rue du Départ, boite 37 75014 Paris France t: +33 (0) 6 81 04 76 85 e: albertineluginbuhl@orange.fr

South East Asia, China and Taiwan Karger Regional Office (Malaysia) CEO Suite Kuala Lumpur Quill 7, 27th Floor Jalan Stesen Sentral 5 KL Sentral Kuala Lumpur 50470 Malaysia t: +60 3 2776 6803 f +60 3 2776 6999 e: service@karger.cn; r.chew@karger.cn

Karger China 10th Floor, Twin Towers (East) B12 Jianguomenwai Avenue Beijing 100022 China t: +86 10 5123 5033 f: +86 10 5123 5122 e: service@karger.cn; r.chew@karger.cn w: www.karger.cn

India, Bangladesh, Sri Lanka

Karger India Plot No. 17, Yusuf Sarai Market B.L. Glass Building, 2nd Floor Sri Aurobindo Marg New Delhi 110 016 India

t: +91 11 46029 633 f: +91 11 46029 634 c: +91 98 91052 128

- e: r.kumar@karger.com
- w: www.karger.com

KARGER

© 2014 S. Karger AG, Basel

The Guidelines for Authors are available at: www.karger.com/crd_Guidelines

E-Mail karger@karger.com www.karger.com

to the subscription source.

Change of Address: Both old and new address should be sent

Japan Karger Japan, Inc. Shiba Daimon Asahi Bldg. 2F

> e: publisher@karger.jp w: www.karger.jp

SAVE THE DATE! CARDIOSTIM 2014 EHRAEUROPACE



World congress on cardiac electrophysiology

www.cardiostim.com

Invasive & Non-Invasive Electrophysiology - Catheter Ablation - Pacing & Defibrillation - Heart Failure - Cardiac Imaging - Angiogenesis & Genetics - Emerging Cardiovascular Technologies





Information: **Dr Philippe Ritter** • CARDIOSTIM E-mail: cardiostim@wanadoo.fr





Contents

See the journal website for contents



Basel • Freiburg • Paris • London • New York • New Delhi • Bangkok • Beijing • Tokyo • Kuala Lumpur • Singapore • Sydney

FRONTIERS IN CARDIOVASCULAR BIOLOGY

Third Meeting of the ESC Council on Basic Cardiovascular Science FCVBROS

IMPORTANT DATES October 2013

My ESC Services open for Abstract submission, Registration, Hotel accommodation

31 January 2014 Abstract Submission deadline

16 April 2014 Early Bird Registration deadline 5 June 2014 Advance Registration deadline

25 June 2014 Pre-registration deadline

BARCELONA www.escardio.org/FCVB

ESC Working Groups on: Atherosclerosis and Vascular Biology - Cardiac Cellular Electrophysiology - Cardiovascular Pharmacology and Drug Therapy -Cellular Biology of the Heart - Coronary Pathophysiology and Microcirculation - Development, Anatomy and Pathology - Myocardial Function - Thrombosis Sister Societies: European Vascular Biology Organisation - International Society for Heart Research European Section - European Council for Cardiovascular Research - European Society for Microcirculation - Association for European Cardiovascular Pathology











INCOMENS

4-6





ESC Council on Basic Cardinoscular Science

ESC CONGRESS **BARCELONA 2014**

Where everything comes together

<u> 30 August – 3 September</u>





Clinical case submission Mid March - I May Hot Lines, Clinical Trial Updates & Registries submission Early Registration deadline

Late Registration deadline

Spotlight: Innovation and the Heart

5 days of scientific Sessions 150 CV Topics 30 000 healthcare professionals from 145 countries 10 000 abstracts submitted 130 industry sponsored sessions 200 exhibiting companies & all year long on ESC Congress 365



F14254

www.escardio.org/ESC2014

31 May

31 July









Glasgow, UK September 13-17 **RSE 2014** Submit yo abstracts February

INNOVATION **EDUCATION INTERVENTION**

CIRSE 2014, Europe's most comprehensive forum for minimally invasive imageguided therapy, will offer more than 250 hours of educational and scientific presentations, including hands-on workshops, foundation courses, learning centres, industry symposia, an all-electronic poster exhibition and the largest CIRSE exhibition ever.

TTT

www.cirse.org

HHR I

MAIN TOPICS

Vascular Interventions Transcatheter Embolisation Non-Vascular Interventions Interventional Oncology Neurointerventions IR Management



Cardiovascular and Interventional Radiological Society of Europe

An excellent overview of recent advances in diagnosis, classification and treatment



Pulmonary Vascular Disorders



Pulmonary Vascular Disorders

Editors **Marc Humbert Rogerio Souza** Gérald Simonneau

Contents

Foreword Preface

- Updated Clinical Classification of Pulmonary Hypertension: Montani, D.; Simonneau, G.
- Pathology of Pulmonary Arterial Hypertension: Dorfmüller, P. Invasive Rest and Exercise Hemodynamics in the
- Modern Management of Pulmonary Vascular Disease: An Expanding Role in the Future: Whyte, K.F.; Hervé, P.; Hoette, S.; Chemla, D. Exercise Testing in Pulmonary Arterial
- Hypertension: Provencher, S.; Mainguy, V. Noninvasive Exploration of the Pulmonary Circulation and the Right Heart:

Vonk Noordegraaf, A.; Peacock, A.; Naeije, R. Biomarkers in Pulmonary Arterial

- Hypertension: Souza, R.; Hoette, S.; Dias, B.; Jardim, C.
- Genetics of Pulmonary Arterial Hypertension and the Concept of Heritable Pulmonary Arterial Hypertension: Girerd, B.; Montani, D.; Yaici, A.; Eyries, M.; Coulet, F.; Soubrier, F.; Humbert, M.
- Drug- and Toxin-Induced Pulmonary Arterial Hypertension: Price, L.; Bouillon, K.; Wort, S.J.;

KARGER

KI12200

Progress in Respiratory Research, Vol. 41 Series Editor: Bolliger, C.T. (Cape Town) ISSN 1422–2140 / e-ISSN 1662–3932 Pulmonary Vascular Disorders

Editors: Humbert, M. (Clamart); Souza, R. (Sao Paulo); Simonneau, G. (Clamart) X + 290 p., 82 fig., 21 in color, 45 tab., hard cover, 2012 CHF 212.- / EUR 177.- / USD 249.00 Frices subject to change EUR price for Germany, USD price for USA only ISBN 978–3–8055–9914–6 e-ISBN 978-3-8055-9915-3



Humbert, M.

- Idiopathic Pulmonary Arterial Hypertension and Its Prognosis in the Modern Management Era in Developed and Developing Countries: Jiang, X.; Humbert, M.; Jing, Z.-C.
- Pulmonary Arterial Hypertension Complicating Connective Tissue Disorders: Le Pavec, J.; Hassoun, P.M.
- Pulmonary Arterial Hypertension and HIV and Other Viral Infections: Degano, B.; Valmary, S.; Sitbon, O.; Humbert, M.
- Portopulmonary Hypertension and Hepatopulmonary Syndrome: Savale, L.; Hervé, P.; Sitbon, O.
- Pulmonary Hypertension in Congenital Heart Diseases: Tissot, C.; Beghetti, M.
- Pulmonary Hypertension in Sickle Cell Disease: Parent, F.; Savale, L.; Maitre, B.; Simonneau, G.
- Schistosomiasis and Pulmonary Hypertension: Fernandes, C.J.C.; Jardim, C.; Hovnanian, A.;
- Hoette, S.; Morinaga, L.K.; Souza, R. Pulmonary Veno-Occlusive Disease: Montani, D.; Huertas, A.; Dorfmüller, P.; Humbert, M.
- Pulmonary Hypertension and Left Heart Disease: Adir, Y.; Galiè, N.
- Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease: Weitzenblum, E.:

www.karger.com/prrer

Please send: ____ copy/ies

Postage and handling free with prepayment

Payment:

- Please charge to my credit card
- 0 American Express Diners ш □ MasterCard 🗌 Visa
- Card No.: đ

ε

-

- σ Exp. date:
- 0 CVV/CVC

(3 digits in the signature field on the back of Visa and MasterCard)

Check enclosed Please bill me

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

Chaouat, A.; Canuet, M.; Ducloné, A.; Kessler, R. Pulmonary Hypertension Complicating Interstitial and Granulomatous Lung Diseases: Nunes, H.;

- Uzunhan, Y.; Gille, T.; Dauriat, G.; Brauner, M.; Kambouchner, M.; Valeyre, D.
- High-Altitude Pulmonary Hypertension: Di, R.-M.; Jing, Z.-C.
- Acute Pulmonary Venous Thromboembolic Disease: Sanchez, O.; Meyer, G.
- Anticoagulation for Venous Thromboembolism in the Modern Management Era: Le Gal, G.; Lerover, C.; Mottier, D.
- Chronic Thromboembolic Pulmonary Hypertension: Lang, I.M.; Jais, X.
- Medical Treatment of Pulmonary Arterial Hypertension: O'Callaghan, D.S.; Gaine, S.P.
- Lung Transplantation and Role for Novel Extracorporeal Support in Pulmonary Hypertension: Hoeper, M.M.
- Atrial Septostomy: Vachiéry, J.-L.
- Pulmonary Vascular Disorders in Hereditary Hemorrhagic Telangiectasia: Cottin, V.;
- Khouatra, C.; Dupuis-Girod, S.; Cordier, J.-F. Future Perspectives in Pulmonary Arterial

Hypertension: Rubin, L.J.

Author and Subject Index

Fax: +41 61 306 12 34

S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland) E-Mail orders@karger.ch, www.karger.com

Name/Address:

Date:

Signature: